[96a5a0]: / output / allTrials / identified / NCT05696782_identified.json

Download this file

783 lines (783 with data), 35.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
{
"info": {
"nct_id": "NCT05696782",
"official_title": "Phase II Pilot Study of Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer",
"inclusion_criteria": "* Patients must have Stage II or Stage III nonsmall cell lung cancer confirmed by histologic or cytologic documentation and by clinical assessment. Staging is defined according to the American Joint Committee on Cancer Staging Manual, 8th Edition (2017).\n* Unresectable or medically inoperable as determined by the investigator.\n* The participant has definitive radiation therapy (e.g., 54 Gy to 66 Gy in 30 to 35 fractions) for lung cancer that is either (a) planned to start within the next 28 days, or (b) currently being administered, or (c) has been completed within the last 14 days.\n* Platinum-based chemotherapy for lung cancer that is either (a) planned to start within the next 28 days, (b) currently being administered, or (c) has been completed within the last 14 days. Chemotherapy must be for at least two cycles and be administered either before radiation therapy (\"induction\" or \"sequential\") or during radiation therapy (\"concurrent\").\n* Consolidation Durvalumab is planned for nonsmall cell lung cancer after radiation and chemotherapy.\n* Eighteen years old or greater.\n* ECOG performance status of 0-2.\n* Life expectancy of greater than three months.\n* Patients with sexual relationships in which either they or their partner may become pregnant must use contraception during the study treatment period.\n* Ability to understand and be willing to sign an IRB-approved informed consent document directly or via a legally authorized representative.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Uncontrolled respiratory symptoms (i.e., cough, dyspnea, fevers, chest pain, or an increase from baseline oxygen requirements) that are interfering with activities of daily living.\n* Nonsmall cell lung cancer is known to have a tumor with a mutation in EGFR associated with sensitivity to first-line therapy with a tyrosine kinase inhibitor (i.e., Ex19del or L858R). Testing for EGFR mutation must have been attempted for study enrollment. If EGFR testing is inconclusive (e.g., the biopsy's quantity or quality is not sufficient for testing to be performed) and there is low clinical suspicion for the presence of an EGFR mutation as determined by the investigator, then the patient is eligible.\n* Prior exposure to an immune checkpoint inhibitor targeting CTLA-4, PD-1, or PD-L1.\n* Active autoimmune disease requiring systemic immunosuppression at the time of enrollment.\n* History of autoimmune pneumonitis requiring high-dose systemic steroids (equivalent prednisone >20 mg/day for more than one week).\n* Uncontrolled intercurrent illness includes ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients who are pregnant or breastfeeding.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients must have Stage II or Stage III nonsmall cell lung cancer confirmed by histologic or cytologic documentation and by clinical assessment. Staging is defined according to the American Joint Committee on Cancer Staging Manual, 8th Edition (2017).",
"criterions": [
{
"exact_snippets": "Stage II or Stage III nonsmall cell lung cancer",
"criterion": "nonsmall cell lung cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"Stage II",
"Stage III"
]
}
]
},
{
"exact_snippets": "confirmed by histologic or cytologic documentation",
"criterion": "nonsmall cell lung cancer confirmation",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologic",
"cytologic"
]
}
]
},
{
"exact_snippets": "confirmed ... by clinical assessment",
"criterion": "nonsmall cell lung cancer confirmation",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "clinical assessment"
}
]
}
]
},
{
"line": "* Unresectable or medically inoperable as determined by the investigator.",
"criterions": [
{
"exact_snippets": "Unresectable",
"criterion": "resectability",
"requirements": [
{
"requirement_type": "status",
"expected_value": "unresectable"
}
]
},
{
"exact_snippets": "medically inoperable",
"criterion": "operability",
"requirements": [
{
"requirement_type": "status",
"expected_value": "medically inoperable"
}
]
}
]
},
{
"line": "* The participant has definitive radiation therapy (e.g., 54 Gy to 66 Gy in 30 to 35 fractions) for lung cancer that is either (a) planned to start within the next 28 days, or (b) currently being administered, or (c) has been completed within the last 14 days.",
"criterions": [
{
"exact_snippets": "definitive radiation therapy (e.g., 54 Gy to 66 Gy in 30 to 35 fractions)",
"criterion": "radiation therapy",
"requirements": [
{
"requirement_type": "type",
"expected_value": "definitive"
},
{
"requirement_type": "dose",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 54,
"unit": "Gy"
},
{
"operator": "<=",
"value": 66,
"unit": "Gy"
}
]
}
},
{
"requirement_type": "fractions",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 30,
"unit": "fractions"
},
{
"operator": "<=",
"value": 35,
"unit": "fractions"
}
]
}
}
]
},
{
"exact_snippets": "lung cancer",
"criterion": "lung cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "planned to start within the next 28 days",
"criterion": "radiation therapy start date",
"requirements": [
{
"requirement_type": "planned start",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 28,
"unit": "days"
}
]
}
}
]
},
{
"exact_snippets": "currently being administered",
"criterion": "radiation therapy administration status",
"requirements": [
{
"requirement_type": "current administration",
"expected_value": true
}
]
},
{
"exact_snippets": "completed within the last 14 days",
"criterion": "radiation therapy completion date",
"requirements": [
{
"requirement_type": "completion",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 14,
"unit": "days"
}
]
}
}
]
}
]
},
{
"line": "* Platinum-based chemotherapy for lung cancer that is either (a) planned to start within the next 28 days, (b) currently being administered, or (c) has been completed within the last 14 days. Chemotherapy must be for at least two cycles and be administered either before radiation therapy (\"induction\" or \"sequential\") or during radiation therapy (\"concurrent\").",
"criterions": [
{
"exact_snippets": "Platinum-based chemotherapy for lung cancer",
"criterion": "chemotherapy type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "platinum-based"
}
]
},
{
"exact_snippets": "Platinum-based chemotherapy for lung cancer",
"criterion": "cancer type",
"requirements": [
{
"requirement_type": "type",
"expected_value": "lung cancer"
}
]
},
{
"exact_snippets": "planned to start within the next 28 days",
"criterion": "chemotherapy timing",
"requirements": [
{
"requirement_type": "planned start",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
},
{
"exact_snippets": "currently being administered",
"criterion": "chemotherapy timing",
"requirements": [
{
"requirement_type": "current status",
"expected_value": "currently administered"
}
]
},
{
"exact_snippets": "completed within the last 14 days",
"criterion": "chemotherapy timing",
"requirements": [
{
"requirement_type": "completion",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
]
},
{
"exact_snippets": "Chemotherapy must be for at least two cycles",
"criterion": "chemotherapy cycles",
"requirements": [
{
"requirement_type": "minimum cycles",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "cycles"
}
}
]
},
{
"exact_snippets": "administered either before radiation therapy (\"induction\" or \"sequential\") or during radiation therapy (\"concurrent\")",
"criterion": "chemotherapy administration timing relative to radiation",
"requirements": [
{
"requirement_type": "timing",
"expected_value": [
"before radiation therapy",
"during radiation therapy"
]
}
]
}
]
},
{
"line": "* Consolidation Durvalumab is planned for nonsmall cell lung cancer after radiation and chemotherapy.",
"criterions": [
{
"exact_snippets": "nonsmall cell lung cancer",
"criterion": "nonsmall cell lung cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "after radiation and chemotherapy",
"criterion": "prior treatment",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": [
"radiation",
"chemotherapy"
]
}
]
}
]
},
{
"line": "* Eighteen years old or greater.",
"criterions": [
{
"exact_snippets": "Eighteen years old or greater.",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* ECOG performance status of 0-2.",
"criterions": [
{
"exact_snippets": "ECOG performance status of 0-2.",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Life expectancy of greater than three months.",
"criterions": [
{
"exact_snippets": "Life expectancy of greater than three months.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Patients with sexual relationships in which either they or their partner may become pregnant must use contraception during the study treatment period.",
"criterions": [
{
"exact_snippets": "Patients with sexual relationships in which either they or their partner may become pregnant",
"criterion": "sexual relationships with pregnancy risk",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "must use contraception during the study treatment period",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
},
{
"line": "* Ability to understand and be willing to sign an IRB-approved informed consent document directly or via a legally authorized representative.",
"criterions": [
{
"exact_snippets": "Ability to understand",
"criterion": "cognitive ability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "be willing to sign an IRB-approved informed consent document",
"criterion": "willingness to consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Uncontrolled respiratory symptoms (i.e., cough, dyspnea, fevers, chest pain, or an increase from baseline oxygen requirements) that are interfering with activities of daily living.",
"criterions": [
{
"exact_snippets": "Uncontrolled respiratory symptoms (i.e., cough, dyspnea, fevers, chest pain, or an increase from baseline oxygen requirements)",
"criterion": "respiratory symptoms",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "cough",
"criterion": "cough",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "dyspnea",
"criterion": "dyspnea",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "fevers",
"criterion": "fevers",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "chest pain",
"criterion": "chest pain",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "an increase from baseline oxygen requirements",
"criterion": "oxygen requirements",
"requirements": [
{
"requirement_type": "change",
"expected_value": "increase from baseline"
}
]
},
{
"exact_snippets": "interfering with activities of daily living",
"criterion": "interference with activities of daily living",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Nonsmall cell lung cancer is known to have a tumor with a mutation in EGFR associated with sensitivity to first-line therapy with a tyrosine kinase inhibitor (i.e., Ex19del or L858R). Testing for EGFR mutation must have been attempted for study enrollment. If EGFR testing is inconclusive (e.g., the biopsy's quantity or quality is not sufficient for testing to be performed) and there is low clinical suspicion for the presence of an EGFR mutation as determined by the investigator, then the patient is eligible.",
"criterions": [
{
"exact_snippets": "Nonsmall cell lung cancer",
"criterion": "nonsmall cell lung cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "tumor with a mutation in EGFR",
"criterion": "EGFR mutation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sensitivity to first-line therapy with a tyrosine kinase inhibitor (i.e., Ex19del or L858R)",
"criterion": "sensitivity to tyrosine kinase inhibitor",
"requirements": [
{
"requirement_type": "sensitivity",
"expected_value": true
}
]
},
{
"exact_snippets": "Testing for EGFR mutation must have been attempted",
"criterion": "EGFR mutation testing",
"requirements": [
{
"requirement_type": "attempt",
"expected_value": true
}
]
},
{
"exact_snippets": "EGFR testing is inconclusive",
"criterion": "EGFR testing result",
"requirements": [
{
"requirement_type": "conclusiveness",
"expected_value": "inconclusive"
}
]
},
{
"exact_snippets": "low clinical suspicion for the presence of an EGFR mutation as determined by the investigator",
"criterion": "clinical suspicion for EGFR mutation",
"requirements": [
{
"requirement_type": "level",
"expected_value": "low"
}
]
}
]
},
{
"line": "* Prior exposure to an immune checkpoint inhibitor targeting CTLA-4, PD-1, or PD-L1.",
"criterions": [
{
"exact_snippets": "Prior exposure to an immune checkpoint inhibitor targeting CTLA-4",
"criterion": "immune checkpoint inhibitor exposure",
"requirements": [
{
"requirement_type": "target",
"expected_value": "CTLA-4"
}
]
},
{
"exact_snippets": "Prior exposure to an immune checkpoint inhibitor targeting ... PD-1",
"criterion": "immune checkpoint inhibitor exposure",
"requirements": [
{
"requirement_type": "target",
"expected_value": "PD-1"
}
]
},
{
"exact_snippets": "Prior exposure to an immune checkpoint inhibitor targeting ... PD-L1",
"criterion": "immune checkpoint inhibitor exposure",
"requirements": [
{
"requirement_type": "target",
"expected_value": "PD-L1"
}
]
}
]
},
{
"line": "* Active autoimmune disease requiring systemic immunosuppression at the time of enrollment.",
"criterions": [
{
"exact_snippets": "Active autoimmune disease",
"criterion": "autoimmune disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "requiring systemic immunosuppression",
"criterion": "systemic immunosuppression",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
},
{
"exact_snippets": "at the time of enrollment",
"criterion": "time of enrollment",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "at the time of enrollment"
}
]
}
]
},
{
"line": "* History of autoimmune pneumonitis requiring high-dose systemic steroids (equivalent prednisone >20 mg/day for more than one week).",
"criterions": [
{
"exact_snippets": "History of autoimmune pneumonitis",
"criterion": "autoimmune pneumonitis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "requiring high-dose systemic steroids (equivalent prednisone >20 mg/day for more than one week)",
"criterion": "systemic steroid use",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": {
"operator": ">",
"value": 20,
"unit": "mg/day"
}
},
{
"requirement_type": "duration",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "week"
}
}
]
}
]
},
{
"line": "* Uncontrolled intercurrent illness includes ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
"criterions": [
{
"exact_snippets": "ongoing or active infection",
"criterion": "infection",
"requirements": [
{
"requirement_type": "status",
"expected_value": "ongoing or active"
}
]
},
{
"exact_snippets": "symptomatic congestive heart failure",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "symptoms",
"expected_value": "symptomatic"
}
]
},
{
"exact_snippets": "unstable angina pectoris",
"criterion": "angina pectoris",
"requirements": [
{
"requirement_type": "stability",
"expected_value": "unstable"
}
]
},
{
"exact_snippets": "cardiac arrhythmia",
"criterion": "cardiac arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
"criterion": "psychiatric illness/social situations",
"requirements": [
{
"requirement_type": "impact on compliance",
"expected_value": "would limit compliance with study requirements"
}
]
}
]
},
{
"line": "* Patients who are pregnant or breastfeeding.",
"criterions": [
{
"exact_snippets": "Patients who are pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}